SCHEMBL3065802

SCHEMBL3065802

CN(CCCNCC(=O)c1c(I)c(NC(=O)CO)c(I)c(C(=O)N(CCO)CC(O)CO)c1I)C(=O)c1c(I)c(NC(=O)CO)c(I)c(C(=O)N(CCO)CC(O)CO)c1I

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3065804 0.91 LMNA (0.50) LMNA
SCHEMBL9390696 0.88 LMNA (0.52) LMNA
SCHEMBL13247606 0.84 LMNA (0.54) LMNA
SCHEMBL13247505 0.82 LMNA (0.57) LMNA
SCHEMBL3061902 0.82 LMNA (0.46) LMNA
SCHEMBL9928663 0.82 LMNA (0.51) LMNA
SCHEMBL13247584 0.81 LMNA (0.58) LMNA
SCHEMBL12995530 0.81 LMNA (0.48) LMNA
SCHEMBL9976300 0.81 LMNA (0.60) LMNA
SCHEMBL13247527 0.81 LMNA (0.57) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100221189-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2010-09-02 US claimed
EP-2200656-A1 CONTRAST AGENTS GE Healthcare AS (NO) 2010-06-30 EP claimed
WO-2009047319-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2009-04-16 WO claimed
US-8202511-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-06-19 US disclosed
US-20100221189-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221189-A1 CONTRAST AGENTS NR1I3, NR1I2, NR1D2 LMNA 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.